Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 7/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365917 | 0.93 | TNKS (0.53) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5375100 | 0.91 | KMT2A (0.45) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5378100 | 0.91 | TNKS (0.52) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5371693 | 0.89 | TNKS (0.41) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5378040 | 0.89 | TNKS (0.41) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5374180 | 0.89 | TNKS (0.46) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5365963 | 0.89 | CTSS (0.47) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5376461 | 0.86 | TNKS (0.43) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5371401 | 0.84 | TNKS (0.41) | TNKSSMN1; SMN2CALCRLDRD2DRD4 | |
| SCHEMBL5374639 | 0.83 | TNKS (0.52) | TNKSSMN1; SMN2CALCRLDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | TNKS 2480/4885SMN1; SMN2 3515/4885CALCRL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.